Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer. 153Sm-DOTMP is a novel kit-based bone-seeking targeted radiopharmaceutical candidate that uses a “next generation” chelating agent to deliver a proprietary formulation of Samarium-153 radioisotope.
Read the full article: Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform //
Source: https://www.globenewswire.com/news-release/2024/02/07/2825600/0/en/Telix-Signs-Agreement-to-Acquire-QSAM-Biosciences-and-Its-Bone-Cancer-Targeting-Platform.html